Germany’s Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks
(This April 28 story has been corrected to clarify the deal’s regulatory status in Europe, in paragraph 11) By Sabrina Valle and Ludwig Burger NEW YORK/FRANKFURT (Reuters) – Germany’s Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead …
Germany’s Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks Read More »










